Skip to main content



Toll-Like Receptor 4 activation and function in diseases: an integrated chemical-biology approach

  TOLLerant is a Marie Sklodowska-Curie Innovative Training Network (MSCA-ITN) funded by Horizon 2020 EU program and coordinated by Prof. Francesco Peri of the University of Milano Bicocca (UNIMIB). The multidisciplinary research project is focused on the study of molecular mechanisms of innate immunity, in particular Toll-like Receptors (TLR) activation and signaling and their therapeutic targeting.

The Consortium

TOLLerant consists of 8 academic and 2 industrial full partners representing 5 countries all across Europe and 3 associate partners, 2 from Europe and one from USA. The PIs expertise covers all areas of chemistry, biology, immunology, biochemistry, medicine and biophysics. In total, 13 Early Stage Researchers (ESRs) have been appointed by the TOLLerant consortium.

Project Aims

To study the role of the human TLR4 (Toll Like Receptor 4) in a number of infectious diseases including sepsis and septic shock, and inflammatory and autoimmune syndromes including neuroinflammatory and neurodegenerative diseases such as Alzheimer's, Parkinson's and ALS (amyotrophic lateral sclerosis).

TOLLerant is then aimed at molecules capable of inhibiting the TLR4. These molecules will be hit and lead compounds to develop drugs targeting diseases in which TLR4 is involved and for which there is still no specific and efficient pharmacological treatment.

To train Early Stage Researchers (ESR) by inserting them in local and EU PhD programs.

Project Duration: January 2015 - December 2018

Acronym: TOLLerant

ID: 642157

color contrast
text size
highlighting content
zoom in